Share Price and Basic Stock Data
Last Updated: February 2, 2026, 5:04 pm
| PEG Ratio | 105.03 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Caprolactam Chemicals Ltd operates in the chemicals sector, specifically within inorganic chemicals like caustic soda and soda ash. The company reported a market capitalization of ₹32.1 Cr and a current share price of ₹69.7. Over the past years, revenue trends have exhibited volatility, with sales declining from ₹9.84 Cr in FY 2023 to ₹6.96 Cr in FY 2024, and further to ₹6.74 Cr in FY 2025. Quarterly sales figures also indicate a downward trend, with ₹2.51 Cr in September 2022 dropping to ₹1.97 Cr by September 2023. The trailing twelve months (TTM) revenue stood at ₹8.82 Cr, reflecting ongoing challenges in maintaining consistent sales performance. The operating profit margin (OPM) was reported at 27.97%, indicative of the company’s capacity to manage costs effectively, although it has seen fluctuations from highs of 50.60% in September 2022 to lows of 22.84% in September 2023. Overall, while there are signs of operational resilience, the revenue trajectory requires close monitoring to ensure sustainable growth.
Profitability and Efficiency Metrics
Caprolactam Chemicals Ltd reported a net profit of ₹0.01 Cr for the latest financial year, which represents a significant decline from ₹2.55 Cr in FY 2023. The profitability metrics reveal a stark contrast in performance, with the net profit margin decreasing from 25.89% in FY 2023 to -10.51% in FY 2025. The interest coverage ratio (ICR) stood at 2.44x, suggesting that the company can meet its interest obligations, albeit with limited buffer. The return on equity (ROE) was reported at 13.7%, while return on capital employed (ROCE) was considerably lower at 0.48%, indicating potential inefficiencies in capital utilization. The cash conversion cycle (CCC) was notably long at 144.54 days, reflecting challenges in managing working capital. Overall, while OPM remains relatively strong, the declining net profit and efficiency ratios underline the need for strategic adjustments to enhance profitability.
Balance Sheet Strength and Financial Ratios
Caprolactam Chemicals Ltd’s balance sheet reflects a total debt of ₹9.04 Cr against total assets of ₹15.40 Cr, resulting in a debt-to-equity ratio of 1.80x. This level of leverage is above the typical sector average, indicating heightened financial risk. Reserves stood at ₹0.72 Cr, which is a slight decrease from ₹0.95 Cr in FY 2024, suggesting limited retained earnings to cushion against operational challenges. The current ratio of 0.38x and quick ratio of 0.34x indicate potential liquidity issues, as both ratios are below the ideal threshold of 1. A price-to-book value (P/BV) ratio of 4.21x suggests that the stock may be overvalued relative to its book value, which was reported at ₹10.50 per share. The company’s ability to sustain its financial health hinges on effective management of liabilities and enhancing its equity base to mitigate risks associated with high leverage.
Shareholding Pattern and Investor Confidence
As of September 2025, Caprolactam Chemicals Ltd had a promoter holding of 54.05%, indicating a strong management commitment to the company. The public shareholding stood at 45.94%, with a total of 8,142 shareholders. Over the past year, promoter holdings have gradually increased from 52.60% in December 2022, reflecting confidence from the management in the company’s strategic direction. However, the absence of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) may signal a lack of institutional interest, which could impact liquidity and market perception. The slight decline in public ownership from 47.40% in December 2022 to 45.94% in September 2025 may raise concerns regarding investor sentiment. The dynamics of shareholding highlight a need for improved communication with investors to bolster confidence and attract a broader base of institutional support.
Outlook, Risks, and Final Insight
The outlook for Caprolactam Chemicals Ltd presents a mixed scenario. On one hand, the company has demonstrated strong operational profitability with a stable operating profit margin, which could be leveraged to improve overall financial performance. However, the declining sales, net profit, and high leverage present significant risks that could hamper future growth. The long cash conversion cycle indicates challenges in working capital management, which could further strain liquidity. Should the company successfully implement strategies to enhance revenue and manage costs, it may improve its financial health and attract institutional interest. Conversely, failure to address these operational inefficiencies could lead to further declines in profitability and investor confidence. The company’s ability to navigate these challenges will be crucial in determining its future trajectory in the competitive chemicals sector.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Caprolactam Chemicals Ltd | 32.1 Cr. | 69.7 | 81.0/37.5 | 3,207 | 11.6 | 0.00 % | 0.48 % | 13.7 % | 10.0 |
| Standard Industries Ltd | 102 Cr. | 15.9 | 26.7/13.0 | 20.4 | 0.00 % | 7.81 % | 10.5 % | 5.00 | |
| Gujarat Alkalies & Chemicals Ltd | 3,455 Cr. | 470 | 700/418 | 23,031 | 759 | 3.34 % | 0.34 % | 1.13 % | 10.0 |
| GHCL Ltd | 4,719 Cr. | 513 | 714/500 | 9.31 | 396 | 2.33 % | 24.2 % | 18.6 % | 10.0 |
| Tata Chemicals Ltd | 17,940 Cr. | 704 | 1,027/692 | 66.0 | 877 | 1.51 % | 3.96 % | 1.20 % | 10.0 |
| Industry Average | 5,357.00 Cr | 361.43 | 5,274.20 | 392.00 | 1.25% | 7.11% | 8.14% | 9.17 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2.51 | 2.37 | 2.22 | 2.06 | 1.97 | 1.49 | 1.44 | 1.12 | 1.71 | 2.29 | 1.61 | 2.56 | 2.36 |
| Expenses | 1.24 | 1.28 | 1.51 | 1.30 | 1.52 | 1.20 | 0.77 | 0.87 | 1.14 | 1.82 | 1.38 | 1.51 | 1.70 |
| Operating Profit | 1.27 | 1.09 | 0.71 | 0.76 | 0.45 | 0.29 | 0.67 | 0.25 | 0.57 | 0.47 | 0.23 | 1.05 | 0.66 |
| OPM % | 50.60% | 45.99% | 31.98% | 36.89% | 22.84% | 19.46% | 46.53% | 22.32% | 33.33% | 20.52% | 14.29% | 41.02% | 27.97% |
| Other Income | 0.01 | 0.00 | -0.01 | 0.15 | 0.00 | 0.00 | 0.03 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.02 |
| Interest | 0.14 | 0.14 | 0.15 | 0.14 | 0.13 | 0.11 | 0.12 | 0.14 | 0.14 | 0.17 | 0.18 | 0.18 | 0.19 |
| Depreciation | 0.22 | 0.33 | 0.39 | 0.37 | 0.39 | 0.40 | 0.42 | 0.38 | 0.40 | 0.40 | 0.41 | 0.38 | 0.39 |
| Profit before tax | 0.92 | 0.62 | 0.16 | 0.40 | -0.07 | -0.22 | 0.16 | -0.27 | 0.03 | -0.09 | -0.36 | 0.49 | 0.10 |
| Tax % | 25.00% | -17.74% | 0.00% | 25.00% | -28.57% | -31.82% | 31.25% | 0.00% | 0.00% | -66.67% | 25.00% | 24.49% | -20.00% |
| Net Profit | 0.69 | 0.74 | 0.17 | 0.30 | -0.06 | -0.16 | 0.12 | -0.27 | 0.04 | -0.03 | -0.45 | 0.36 | 0.13 |
| EPS in Rs | 1.50 | 1.61 | 0.37 | 0.65 | -0.13 | -0.35 | 0.26 | -0.59 | 0.09 | -0.07 | -0.98 | 0.78 | 0.28 |
Last Updated: December 27, 2025, 4:03 pm
Below is a detailed analysis of the quarterly data for Caprolactam Chemicals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 2.36 Cr.. The value appears to be declining and may need further review. It has decreased from 2.56 Cr. (Jun 2025) to 2.36 Cr., marking a decrease of 0.20 Cr..
- For Expenses, as of Sep 2025, the value is 1.70 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.51 Cr. (Jun 2025) to 1.70 Cr., marking an increase of 0.19 Cr..
- For Operating Profit, as of Sep 2025, the value is 0.66 Cr.. The value appears to be declining and may need further review. It has decreased from 1.05 Cr. (Jun 2025) to 0.66 Cr., marking a decrease of 0.39 Cr..
- For OPM %, as of Sep 2025, the value is 27.97%. The value appears to be declining and may need further review. It has decreased from 41.02% (Jun 2025) to 27.97%, marking a decrease of 13.05%.
- For Other Income, as of Sep 2025, the value is 0.02 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Jun 2025) to 0.02 Cr., marking an increase of 0.02 Cr..
- For Interest, as of Sep 2025, the value is 0.19 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.18 Cr. (Jun 2025) to 0.19 Cr., marking an increase of 0.01 Cr..
- For Depreciation, as of Sep 2025, the value is 0.39 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.38 Cr. (Jun 2025) to 0.39 Cr., marking an increase of 0.01 Cr..
- For Profit before tax, as of Sep 2025, the value is 0.10 Cr.. The value appears to be declining and may need further review. It has decreased from 0.49 Cr. (Jun 2025) to 0.10 Cr., marking a decrease of 0.39 Cr..
- For Tax %, as of Sep 2025, the value is -20.00%. The value appears to be improving (decreasing) as expected. It has decreased from 24.49% (Jun 2025) to -20.00%, marking a decrease of 44.49%.
- For Net Profit, as of Sep 2025, the value is 0.13 Cr.. The value appears to be declining and may need further review. It has decreased from 0.36 Cr. (Jun 2025) to 0.13 Cr., marking a decrease of 0.23 Cr..
- For EPS in Rs, as of Sep 2025, the value is 0.28. The value appears to be declining and may need further review. It has decreased from 0.78 (Jun 2025) to 0.28, marking a decrease of 0.50.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:00 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3.92 | 2.85 | 4.88 | 3.23 | 4.07 | 5.19 | 6.51 | 6.31 | 2.07 | 9.84 | 6.96 | 6.74 | 8.82 |
| Expenses | 4.03 | 2.46 | 4.05 | 2.76 | 3.18 | 3.31 | 3.99 | 4.14 | 2.64 | 5.17 | 4.79 | 5.22 | 6.41 |
| Operating Profit | -0.11 | 0.39 | 0.83 | 0.47 | 0.89 | 1.88 | 2.52 | 2.17 | -0.57 | 4.67 | 2.17 | 1.52 | 2.41 |
| OPM % | -2.81% | 13.68% | 17.01% | 14.55% | 21.87% | 36.22% | 38.71% | 34.39% | -27.54% | 47.46% | 31.18% | 22.55% | 27.32% |
| Other Income | 0.01 | -0.15 | 0.40 | 0.01 | 0.07 | 0.07 | 0.06 | 0.09 | 0.41 | 0.02 | 0.18 | 0.01 | 0.03 |
| Interest | 0.00 | 0.06 | 0.11 | 0.12 | 0.19 | 0.34 | 0.30 | 0.30 | 0.28 | 0.57 | 0.50 | 0.63 | 0.72 |
| Depreciation | 0.19 | 0.23 | 0.51 | 0.47 | 0.57 | 0.97 | 1.02 | 1.07 | 1.03 | 1.15 | 1.58 | 1.59 | 1.58 |
| Profit before tax | -0.29 | -0.05 | 0.61 | -0.11 | 0.20 | 0.64 | 1.26 | 0.89 | -1.47 | 2.97 | 0.27 | -0.69 | 0.14 |
| Tax % | -6.90% | 0.00% | 14.75% | 0.00% | 15.00% | 23.44% | 24.60% | 26.97% | -12.93% | 14.14% | 29.63% | 4.35% | |
| Net Profit | -0.27 | -0.06 | 0.52 | -0.12 | 0.17 | 0.50 | 0.95 | 0.65 | -1.28 | 2.55 | 0.20 | -0.71 | 0.01 |
| EPS in Rs | -0.59 | -0.13 | 1.13 | -0.26 | 0.37 | 1.09 | 2.07 | 1.41 | -2.78 | 5.54 | 0.43 | -1.54 | 0.01 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 77.78% | 966.67% | -123.08% | 241.67% | 194.12% | 90.00% | -31.58% | -296.92% | 299.22% | -92.16% | -455.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 888.89% | -1089.74% | 364.74% | -47.55% | -104.12% | -121.58% | -265.34% | 596.14% | -391.38% | -362.84% |
Caprolactam Chemicals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 1% |
| 3 Years: | 48% |
| TTM: | 36% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 13% |
| TTM: | 78% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 24% |
| 5 Years: | 23% |
| 3 Years: | -9% |
| 1 Year: | -12% |
| Return on Equity | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 6% |
| 3 Years: | 14% |
| Last Year: | -14% |
Last Updated: September 5, 2025, 2:51 pm
Balance Sheet
Last Updated: February 1, 2026, 2:31 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4.59 | 4.59 | 4.59 | 4.59 | 4.59 | 4.60 | 4.60 | 4.60 | 4.60 | 4.60 | 4.60 | 4.60 | 4.60 |
| Reserves | -3.08 | -3.13 | -2.61 | -2.73 | -2.56 | -2.06 | -1.10 | -0.52 | -1.80 | 0.74 | 0.95 | 0.23 | 0.72 |
| Borrowings | 0.09 | 0.82 | 0.95 | 1.37 | 1.89 | 3.58 | 2.45 | 2.15 | 3.76 | 5.69 | 5.86 | 8.72 | 9.04 |
| Other Liabilities | 0.52 | 1.15 | 0.98 | 1.10 | 2.35 | 1.29 | 1.16 | 0.97 | 3.77 | 0.49 | 0.25 | 0.74 | 1.04 |
| Total Liabilities | 2.12 | 3.43 | 3.91 | 4.33 | 6.27 | 7.41 | 7.11 | 7.20 | 10.33 | 11.52 | 11.66 | 14.29 | 15.40 |
| Fixed Assets | 1.19 | 2.92 | 2.96 | 3.38 | 3.56 | 6.37 | 6.07 | 5.50 | 5.26 | 10.22 | 10.29 | 10.31 | 10.12 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.96 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 0.93 | 0.51 | 0.95 | 0.95 | 2.71 | 1.04 | 1.04 | 1.70 | 1.11 | 1.30 | 1.37 | 3.98 | 5.28 |
| Total Assets | 2.12 | 3.43 | 3.91 | 4.33 | 6.27 | 7.41 | 7.11 | 7.20 | 10.33 | 11.52 | 11.66 | 14.29 | 15.40 |
Below is a detailed analysis of the balance sheet data for Caprolactam Chemicals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 4.60 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 4.60 Cr..
- For Reserves, as of Sep 2025, the value is 0.72 Cr.. The value appears strong and on an upward trend. It has increased from 0.23 Cr. (Mar 2025) to 0.72 Cr., marking an increase of 0.49 Cr..
- For Borrowings, as of Sep 2025, the value is 9.04 Cr.. The value appears to be increasing, which may not be favorable. However, Borrowings exceed Reserves, which may signal higher financial risk. It has increased from 8.72 Cr. (Mar 2025) to 9.04 Cr., marking an increase of 0.32 Cr..
- For Other Liabilities, as of Sep 2025, the value is 1.04 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.74 Cr. (Mar 2025) to 1.04 Cr., marking an increase of 0.30 Cr..
- For Total Liabilities, as of Sep 2025, the value is 15.40 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 14.29 Cr. (Mar 2025) to 15.40 Cr., marking an increase of 1.11 Cr..
- For Fixed Assets, as of Sep 2025, the value is 10.12 Cr.. The value appears to be declining and may need further review. It has decreased from 10.31 Cr. (Mar 2025) to 10.12 Cr., marking a decrease of 0.19 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 5.28 Cr.. The value appears strong and on an upward trend. It has increased from 3.98 Cr. (Mar 2025) to 5.28 Cr., marking an increase of 1.30 Cr..
- For Total Assets, as of Sep 2025, the value is 15.40 Cr.. The value appears strong and on an upward trend. It has increased from 14.29 Cr. (Mar 2025) to 15.40 Cr., marking an increase of 1.11 Cr..
However, the Borrowings (9.04 Cr.) are higher than the Reserves (0.72 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -0.20 | -0.43 | -0.12 | -0.90 | -1.00 | -1.70 | 0.07 | 0.02 | -4.33 | -1.02 | -3.69 | -7.20 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 25.14 | 1.28 | 38.89 | 40.68 | 69.05 | 2.81 | 16.82 | 27.19 | 5.29 | 25.22 | 33.56 | 152.72 |
| Inventory Days | 104.29 | 304.17 | 88.78 | 82.64 | 53.85 | 52.14 | 111.68 | |||||
| Days Payable | 43.45 | 861.81 | 799.05 | 344.34 | 173.52 | 111.73 | 119.85 | |||||
| Cash Conversion Cycle | 85.97 | 1.28 | 38.89 | 40.68 | -488.58 | -707.46 | 16.82 | 27.19 | -256.41 | -94.45 | -26.03 | 144.54 |
| Working Capital Days | 20.48 | -189.54 | -71.80 | -169.50 | -232.27 | -274.28 | -158.11 | -106.43 | -689.44 | -94.22 | -267.46 | -314.64 |
| ROCE % | -17.06% | 11.34% | 27.64% | 0.32% | 10.91% | 19.52% | 25.85% | 19.54% | -18.61% | 40.25% | 6.86% | -0.48% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -1.54 | 0.43 | 5.54 | -2.79 | 1.41 |
| Diluted EPS (Rs.) | -1.54 | 0.43 | 5.54 | -2.79 | 1.41 |
| Cash EPS (Rs.) | 1.91 | 3.87 | 8.05 | -0.53 | 3.73 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 10.50 | 12.06 | 11.61 | 6.08 | 8.87 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 10.50 | 12.06 | 11.61 | 6.08 | 8.87 |
| Revenue From Operations / Share (Rs.) | 14.65 | 15.12 | 21.39 | 4.50 | 13.72 |
| PBDIT / Share (Rs.) | 3.33 | 5.11 | 10.20 | -0.35 | 4.90 |
| PBIT / Share (Rs.) | -0.11 | 1.67 | 7.69 | -2.60 | 2.58 |
| PBT / Share (Rs.) | -1.49 | 0.59 | 6.46 | -3.20 | 1.94 |
| Net Profit / Share (Rs.) | -1.54 | 0.42 | 5.54 | -2.79 | 1.41 |
| PBDIT Margin (%) | 22.75 | 33.81 | 47.66 | -7.87 | 35.72 |
| PBIT Margin (%) | -0.81 | 11.07 | 35.95 | -57.88 | 18.83 |
| PBT Margin (%) | -10.14 | 3.91 | 30.18 | -71.24 | 14.12 |
| Net Profit Margin (%) | -10.51 | 2.83 | 25.89 | -61.97 | 10.31 |
| Return on Networth / Equity (%) | -14.67 | 3.55 | 47.70 | -45.82 | 15.94 |
| Return on Capital Employeed (%) | -1.12 | 10.62 | 44.09 | -21.52 | 29.13 |
| Return On Assets (%) | -4.96 | 1.69 | 22.12 | -12.40 | 9.30 |
| Long Term Debt / Equity (X) | 0.00 | 0.29 | 0.49 | 0.98 | 0.00 |
| Total Debt / Equity (X) | 1.80 | 1.06 | 1.06 | 1.34 | 0.52 |
| Asset Turnover Ratio (%) | 0.51 | 0.60 | 0.90 | 0.23 | 0.90 |
| Current Ratio (X) | 0.38 | 0.24 | 0.34 | 0.21 | 0.53 |
| Quick Ratio (X) | 0.34 | 0.22 | 0.31 | 0.18 | 0.50 |
| Inventory Turnover Ratio (X) | 28.47 | 6.31 | 5.53 | 4.83 | 0.13 |
| Interest Coverage Ratio (X) | 2.44 | 4.73 | 8.26 | -0.58 | 7.58 |
| Interest Coverage Ratio (Post Tax) (X) | -0.12 | 1.40 | 5.49 | -3.64 | 3.19 |
| Enterprise Value (Cr.) | 28.94 | 29.47 | 29.54 | 25.41 | 16.72 |
| EV / Net Operating Revenue (X) | 4.29 | 4.24 | 3.00 | 12.28 | 2.65 |
| EV / EBITDA (X) | 18.88 | 12.53 | 6.30 | -156.02 | 7.42 |
| MarketCap / Net Operating Revenue (X) | 3.01 | 3.40 | 2.45 | 10.54 | 2.39 |
| Price / BV (X) | 4.21 | 4.27 | 4.51 | 7.79 | 3.70 |
| Price / Net Operating Revenue (X) | 3.01 | 3.41 | 2.45 | 10.54 | 2.39 |
| EarningsYield | -0.03 | 0.01 | 0.10 | -0.05 | 0.04 |
After reviewing the key financial ratios for Caprolactam Chemicals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -1.54. This value is below the healthy minimum of 5. It has decreased from 0.43 (Mar 24) to -1.54, marking a decrease of 1.97.
- For Diluted EPS (Rs.), as of Mar 25, the value is -1.54. This value is below the healthy minimum of 5. It has decreased from 0.43 (Mar 24) to -1.54, marking a decrease of 1.97.
- For Cash EPS (Rs.), as of Mar 25, the value is 1.91. This value is below the healthy minimum of 3. It has decreased from 3.87 (Mar 24) to 1.91, marking a decrease of 1.96.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 10.50. It has decreased from 12.06 (Mar 24) to 10.50, marking a decrease of 1.56.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 10.50. It has decreased from 12.06 (Mar 24) to 10.50, marking a decrease of 1.56.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 14.65. It has decreased from 15.12 (Mar 24) to 14.65, marking a decrease of 0.47.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 3.33. This value is within the healthy range. It has decreased from 5.11 (Mar 24) to 3.33, marking a decrease of 1.78.
- For PBIT / Share (Rs.), as of Mar 25, the value is -0.11. This value is below the healthy minimum of 0. It has decreased from 1.67 (Mar 24) to -0.11, marking a decrease of 1.78.
- For PBT / Share (Rs.), as of Mar 25, the value is -1.49. This value is below the healthy minimum of 0. It has decreased from 0.59 (Mar 24) to -1.49, marking a decrease of 2.08.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -1.54. This value is below the healthy minimum of 2. It has decreased from 0.42 (Mar 24) to -1.54, marking a decrease of 1.96.
- For PBDIT Margin (%), as of Mar 25, the value is 22.75. This value is within the healthy range. It has decreased from 33.81 (Mar 24) to 22.75, marking a decrease of 11.06.
- For PBIT Margin (%), as of Mar 25, the value is -0.81. This value is below the healthy minimum of 10. It has decreased from 11.07 (Mar 24) to -0.81, marking a decrease of 11.88.
- For PBT Margin (%), as of Mar 25, the value is -10.14. This value is below the healthy minimum of 10. It has decreased from 3.91 (Mar 24) to -10.14, marking a decrease of 14.05.
- For Net Profit Margin (%), as of Mar 25, the value is -10.51. This value is below the healthy minimum of 5. It has decreased from 2.83 (Mar 24) to -10.51, marking a decrease of 13.34.
- For Return on Networth / Equity (%), as of Mar 25, the value is -14.67. This value is below the healthy minimum of 15. It has decreased from 3.55 (Mar 24) to -14.67, marking a decrease of 18.22.
- For Return on Capital Employeed (%), as of Mar 25, the value is -1.12. This value is below the healthy minimum of 10. It has decreased from 10.62 (Mar 24) to -1.12, marking a decrease of 11.74.
- For Return On Assets (%), as of Mar 25, the value is -4.96. This value is below the healthy minimum of 5. It has decreased from 1.69 (Mar 24) to -4.96, marking a decrease of 6.65.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. It has decreased from 0.29 (Mar 24) to 0.00, marking a decrease of 0.29.
- For Total Debt / Equity (X), as of Mar 25, the value is 1.80. This value exceeds the healthy maximum of 1. It has increased from 1.06 (Mar 24) to 1.80, marking an increase of 0.74.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.51. It has decreased from 0.60 (Mar 24) to 0.51, marking a decrease of 0.09.
- For Current Ratio (X), as of Mar 25, the value is 0.38. This value is below the healthy minimum of 1.5. It has increased from 0.24 (Mar 24) to 0.38, marking an increase of 0.14.
- For Quick Ratio (X), as of Mar 25, the value is 0.34. This value is below the healthy minimum of 1. It has increased from 0.22 (Mar 24) to 0.34, marking an increase of 0.12.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 28.47. This value exceeds the healthy maximum of 8. It has increased from 6.31 (Mar 24) to 28.47, marking an increase of 22.16.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 2.44. This value is below the healthy minimum of 3. It has decreased from 4.73 (Mar 24) to 2.44, marking a decrease of 2.29.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -0.12. This value is below the healthy minimum of 3. It has decreased from 1.40 (Mar 24) to -0.12, marking a decrease of 1.52.
- For Enterprise Value (Cr.), as of Mar 25, the value is 28.94. It has decreased from 29.47 (Mar 24) to 28.94, marking a decrease of 0.53.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.29. This value exceeds the healthy maximum of 3. It has increased from 4.24 (Mar 24) to 4.29, marking an increase of 0.05.
- For EV / EBITDA (X), as of Mar 25, the value is 18.88. This value exceeds the healthy maximum of 15. It has increased from 12.53 (Mar 24) to 18.88, marking an increase of 6.35.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.01. This value exceeds the healthy maximum of 3. It has decreased from 3.40 (Mar 24) to 3.01, marking a decrease of 0.39.
- For Price / BV (X), as of Mar 25, the value is 4.21. This value exceeds the healthy maximum of 3. It has decreased from 4.27 (Mar 24) to 4.21, marking a decrease of 0.06.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.01. This value exceeds the healthy maximum of 3. It has decreased from 3.41 (Mar 24) to 3.01, marking a decrease of 0.40.
- For EarningsYield, as of Mar 25, the value is -0.03. This value is below the healthy minimum of 5. It has decreased from 0.01 (Mar 24) to -0.03, marking a decrease of 0.04.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Caprolactam Chemicals Ltd:
- Net Profit Margin: -10.51%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -1.12% (Industry Average ROCE: 7.11%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -14.67% (Industry Average ROE: 8.14%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -0.12
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.34
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 3 (Industry average Stock P/E: 5)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 1.8
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -10.51%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Inorganic - Caustic Soda/Soda Ash | B-31, MIDC, Mahad, Raigad District Maharashtra 402302 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mrs. Zaver Shankarlal Bhanushali | Chairperson & Managing Director |
| Mr. Siddharth Shankarlal Bhanushali | WholeTime Director & CFO |
| Mr. Viren Jaysukhlal Jasani | Ind. Non-Executive Director |
| Mr. Kamlesh Damji Joisher | Ind. Non-Executive Director |
| Mrs. Poonam Bhavin Bhanushali | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Caprolactam Chemicals Ltd?
Caprolactam Chemicals Ltd's intrinsic value (as of 06 February 2026) is ₹5428.70 which is 7688.67% higher the current market price of ₹69.70, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹32.1 Cr. market cap, FY2025-2026 high/low of ₹81.0/37.5, reserves of ₹0.72 Cr, and liabilities of ₹15.40 Cr.
What is the Market Cap of Caprolactam Chemicals Ltd?
The Market Cap of Caprolactam Chemicals Ltd is 32.1 Cr..
What is the current Stock Price of Caprolactam Chemicals Ltd as on 06 February 2026?
The current stock price of Caprolactam Chemicals Ltd as on 06 February 2026 is ₹69.7.
What is the High / Low of Caprolactam Chemicals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Caprolactam Chemicals Ltd stocks is ₹81.0/37.5.
What is the Stock P/E of Caprolactam Chemicals Ltd?
The Stock P/E of Caprolactam Chemicals Ltd is 3,207.
What is the Book Value of Caprolactam Chemicals Ltd?
The Book Value of Caprolactam Chemicals Ltd is 11.6.
What is the Dividend Yield of Caprolactam Chemicals Ltd?
The Dividend Yield of Caprolactam Chemicals Ltd is 0.00 %.
What is the ROCE of Caprolactam Chemicals Ltd?
The ROCE of Caprolactam Chemicals Ltd is 0.48 %.
What is the ROE of Caprolactam Chemicals Ltd?
The ROE of Caprolactam Chemicals Ltd is 13.7 %.
What is the Face Value of Caprolactam Chemicals Ltd?
The Face Value of Caprolactam Chemicals Ltd is 10.0.